| 查看: 1952 | 回復(fù): 27 | |||
| 本帖產(chǎn)生 2 個(gè) DRDEPI ,點(diǎn)擊這里進(jìn)行查看 | |||
狼行拂曉榮譽(yù)版主 (著名寫手)
~~~~
|
[交流]
金秋之際話“豐收”,有獎(jiǎng)分享經(jīng)驗(yàn)總結(jié)活動(dòng),期待你的參與! 已有10人參與
|
||
|
金秋之際話“豐收”,有獎(jiǎng)分享經(jīng)驗(yàn)總結(jié)活動(dòng),期待你的參與!
【活動(dòng)內(nèi)容】
【活動(dòng)目的】: [ Last edited by 狼行拂曉 on 2015-10-19 at 20:11 ] |

榮譽(yù)版主 (著名寫手)
~~~~
|
活動(dòng)很簡單,大家不要想太復(fù)雜噢,不用長篇大論,可以分享下最近掌握的小技巧之類的,或者簡單的一些經(jīng)驗(yàn)吧。 示例: 以前知道drugfuture可以查找化合物的合成工藝路線,通過引用的專利來追溯原研的化合物專利等等。 最近發(fā)現(xiàn)藥渡網(wǎng)也是個(gè)不錯(cuò)的網(wǎng)站,除了總結(jié)出一些經(jīng)典的工藝路線,還對(duì)批準(zhǔn)上市的藥物中的雜質(zhì)進(jìn)行了列舉,包括雜質(zhì)的化合物結(jié)構(gòu)哦。對(duì)于做仿制藥的立項(xiàng)調(diào)研,或者對(duì)于申報(bào)資料中3.2.S.2.6中工藝路線的選擇都有非常不錯(cuò)的借鑒價(jià)值。 |

超級(jí)版主 (文學(xué)泰斗)
小木蟲科研大使\(^o^)/~

專家顧問 (職業(yè)作家)
|
支持支持,版內(nèi)蟲友參與積極分享以及討論的熱情不是很高。我覺得需要多舉行相關(guān)的交流分享活動(dòng),聯(lián)絡(luò)一群愿意交流分享并為小木蟲的新藥研發(fā)板塊良好發(fā)展盡微薄之力的蟲蟲。 版主更應(yīng)該帶頭,金幣就不要吝嗇了。 ![]() |

專家顧問 (職業(yè)作家)

榮譽(yù)版主 (著名寫手)
~~~~

專家顧問 (職業(yè)作家)

榮譽(yù)版主 (著名寫手)
~~~~

榮譽(yù)版主 (著名寫手)
~~~~

榮譽(yù)版主 (著名寫手)
~~~~
|
美國GDUFA中立卷審查(GDUFA INITIAL COMPLETENESS ASSESSMENT CHECKLIST FOR TYPE II API DMFs)的評(píng)審建議,同時(shí)要結(jié)合不接受標(biāo)準(zhǔn)ANDA Submissions –Refuse-to-Receive Standards Guidance for Industry: 3.2.S.2.1 Contains complete Manufacturer Information on the following for each site: Note: If a late stage intermediate has been outsourced, detailed information regarding the source for each supplier needs to be provided in section 2.3. Separate facilities used for release testing of the API and for additional processing (e.g. micronization) should also be listed. Central File Number or Facility Establishment Identifier numbers should be provided if available. 3.2.S.2.2 Contains Description of Manufacturing Process and Process Controls addressing the following: Note: DMF will not be considered complete for review requirements if the complete process is not included in the DMF or by appropriate reference to another DMF. If the firm chooses intermediates as “starting materials” a determination should be made if information is provided in the DMF to adequately evaluate their controls and effect on the drug substance quality and purity. 3.2.S.2.3 Contains information on the Control of Materials, as follows: Note: Specification, analytical protocol and representative CoA of each reagent/solvent should be provided. 3.2.S.2.4 Contains information for Controls of Critical Steps and Intermediates as follows: For sterile APIs. 3.2.S.4 Information is provided to support the Control of the Drug Substance as follows: Method validation reports may be included in section 3.2.R.3.S. |

| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 能源材料化學(xué)課題組招收碩士研究生8-10名 +4 | 脫穎而出 2026-03-16 | 10/500 |
|
|---|---|---|---|---|
|
[考研] 070303一志愿西北大學(xué)學(xué)碩310找調(diào)劑 +6 | d如愿上岸 2026-03-12 | 9/450 |
|
|
[考研] 0703化學(xué) 305求調(diào)劑 +3 | FY_yy 2026-03-14 | 3/150 |
|
|
[考研] 085600材料與化工 +5 | 安全上岸! 2026-03-16 | 5/250 |
|
|
[考研] 070300化學(xué)319求調(diào)劑 +6 | 錦鯉0909 2026-03-17 | 6/300 |
|
|
[考研] 299求調(diào)劑 +5 | △小透明* 2026-03-17 | 5/250 |
|
|
[考研] 工科材料085601 279求調(diào)劑 +6 | 困于星晨 2026-03-17 | 6/300 |
|
|
[考研] 268求調(diào)劑 +6 | 簡單點(diǎn)0 2026-03-17 | 6/300 |
|
|
[考研] 268求調(diào)劑 +8 | 一定有學(xué)上- 2026-03-14 | 9/450 |
|
|
[考研] 考研化學(xué)學(xué)碩調(diào)劑,一志愿985 +4 | 張vvvv 2026-03-15 | 6/300 |
|
|
[考研] 290求調(diào)劑 +6 | 孔志浩 2026-03-12 | 11/550 |
|
|
[考研] 211本,11408一志愿中科院277分,曾在中科院自動(dòng)化所實(shí)習(xí) +6 | Losir 2026-03-12 | 7/350 |
|
|
[考研] 材料工程專碩274一志愿211求調(diào)劑 +6 | 薛云鵬 2026-03-15 | 6/300 |
|
|
[考研] 275求調(diào)劑 +4 | 太陽花天天開心 2026-03-16 | 4/200 |
|
|
[考研] 274求調(diào)劑 +5 | 時(shí)間點(diǎn) 2026-03-13 | 5/250 |
|
|
[考研] 304求調(diào)劑 +3 | 曼殊2266 2026-03-14 | 3/150 |
|
|
[考研] 學(xué)碩285求調(diào)劑 +13 | Wisjxn 2026-03-12 | 46/2300 |
|
|
[考研] 求調(diào)劑 +5 | 一定有學(xué)上- 2026-03-12 | 5/250 |
|
|
[考研] 328化工專碩求調(diào)劑 +4 | 。,。,。,。i 2026-03-12 | 4/200 |
|
|
[考研] 0817化學(xué)工程與技術(shù)考研312分調(diào)劑 +3 | T123 tt 2026-03-12 | 3/150 |
|